MedRhythms Announces New CMS Reimbursement Code for InTandem Rehabilitation System For Chronic Stroke Gait Impairment
MedRhythms Announces New CMS Reimbursement Code for InTandem Rehabilitation System For Chronic Stroke Gait Impairment
- The Centers for Medicare and Medicaid Services (CMS) assigned a new, unique Health Care Common Procedure Coding System (HCPCS) code to InTandem under Medicare's Durable Medical Equipment (DME) Benefit category
- E3200, as the new code, will go into effect on October 1, 2024
- InTandem is indicated to improve walking and ambulation in chronic stroke and is intended to be used in the home for the physical rehabilitation of ambulatory adults.
- 醫療和醫保服務中心(CMS)根據醫療保健的耐用醫療設備(DME)受益類別,爲InTandem分配了一個新的獨特的醫療保健常用程序編碼系統(HCPCS)代碼。
- 作爲新代碼,E3200將於2024年10月1日生效。
- InTandem適用於改善慢性中風患者行走和步態,旨在用於家庭中成年人的物理康復。
PORTLAND, Maine, Aug. 22, 2024 /PRNewswire/ -- MedRhythms, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) established a new reimbursement code for the company's flagship product, InTandem, the only clinically validated, prescription medical device that delivers rhythmic auditory stimulation (RAS) in the home to improve walking and ambulation in chronic stroke patients.
緬因州波特蘭,2024年8月22日/美通社/ - MedRhythms, Inc.今天宣佈,醫療保健和醫保服務中心(CMS)爲該公司的旗艦產品InTandem制定了新的報銷代碼。InTandem是唯一經過臨床驗證的處方式醫療器械,在家中通過節律性聽覺刺激(RAS)改善慢性中風患者的行走和步態。
In its final determination, CMS established a new HCPCS code to describe InTandem: E3200 (gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only). CMS also determined that InTandem qualified under Medicare's durable medical equipment (DME) benefit category based on InTandem's durability and indication for home use.
在其 最終確定中, CMS制定了一個新的HCPCS代碼來描述InTandem:E3200(步態調節系統,節律性聽覺刺激,包括限制療法軟件,所有元件和配件,僅限處方)。CMS還根據InTandem的耐用性和家庭使用的指示,確定InTandem符合醫療保健的耐用醫療設備(DME)受益類別。
The CMS decision to issue a new code for InTandem underscores recognition of this significant unmet need in chronic stroke. A consistent barrier for patients with chronic stroke is a lack of access to rehabilitation once they have returned to the home.
CMS決定爲InTandem發佈一個新代碼,凸顯出對慢性中風患者這一重大需求的認可。慢性中風患者面臨的一個持久障礙是回家後無法獲得康復治療。
"As a clinician, I'm far too familiar with the challenges stroke patients face in accessing treatment, particularly in the chronic phase of stroke recovery," said Brian Harris, MedRhythms' Co-Founder and CEO. "The establishment of this HCPCS code offers new hope to chronic stroke patients who are battling walking deficits, and advances MedRhythms mission to bring effective care to patients who need and deserve to have access to it."
MedRhythms聯合創始人兼首席執行官Brian Harris表示:「作爲臨床醫生,我對中風患者在獲取治療方面面臨的挑戰非常熟悉,尤其是在中風康復的慢性階段。建立這個HCPCS代碼爲正在與步態缺陷作鬥爭的慢性中風患者帶來新希望,並推進了MedRhythms將有效護理帶給需要並應該獲得護理的患者的使命。」
InTandem delivers individualized, progressive RAS therapy in the home setting, producing gait quality and speed improvements to drive improved health outcomes and reduce the risk of adverse health events common in post-stroke patients. By leveraging wearable, clinical-grade gait sensors and a hardware control unit containing adaptive algorithms and clinically optimized music, InTandem automates the key principles of effective RAS therapy, in combination with best practices for neurorehabilitation interventions: individualization, progression, and challenge. InTandem's unique integration of advanced hardware, software, and best clinical practices enables patients to access this evidence-based intervention independently at home.
InTandem在家庭環境中提供個性化、遞進的RAS療法,改善步態質量和速度,促進改善健康結果,並降低中風後患者常見的不良健康事件的風險。通過利用可穿戴的臨床級步態傳感器以及包含自適應算法和臨床優化音樂的硬件控制單元,InTandem自動化了有效RAS療法的關鍵原則,並與神經康復干預的最佳實踐相結合:個體化、遞進和挑戰。InTandem獨特地結合了先進的硬件、軟件和最佳臨床實踐,使患者能夠獨立在家中進行這種基於證據的干預。
"InTandem's personalized approach, grounded in the neuroscience of RAS and neuroplasticity, positions InTandem as an effective clinical intervention for chronic stroke patients seeking to improve their walking ability and overall mobility," said Dr. Alexander Pantelyat, Associate Professor of Neurology at the Johns Hopkins University School of Medicine.
約翰斯·霍普金斯大學醫學院的神經病學副教授亞歷山大·潘特利亞特博士說:「InTandem基於RAS和神經可塑性的神經科學的個性化方法,使其成爲慢性中風患者尋求改善步行能力和整體行動能力的有效臨床干預。」
Jennifer Lavanture, MedRhythms' VP of Business Development and Corporate Strategy, continued: "These CMS decisions are crucial developments in the path to provide access to this groundbreaking treatment to patients. MedRhythms commends CMS for their thoughtful consideration, and we greatly appreciate the time and efforts of the many patients, clinicians, and stakeholders who provided input and support throughout this process." The new code for InTandem will become effective October 1, 2024.
MedRhythms的業務拓展和企業策略副總裁Jennifer Lavanture繼續說:「這些CMS的決定是向患者提供這種開創性治療途徑的關鍵發展。MedRhythms讚揚CMS的周到考慮,我們非常感謝在整個過程中提供意見和支持的衆多患者、臨床醫生和利益相關者的時間和努力。」 InTandem的新代碼將於2024年10月1日生效。
InTandem, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2020 and was listed as a Class II medical device in July 2023, is designed to be used by people with chronic stroke gait impairment. Results of a multi-site randomized controlled trial that demonstrated the clinical benefits and safety of InTandem were published in Nature Communications earlier this year.
InTandem於2020年獲得了美國食品和藥物管理局(FDA)的突破性器械認定,並於2023年7月被列爲二類醫療器械,旨在供慢性中風步行障礙者使用。一項多中心隨機對照試驗的結果顯示了InTandem的臨床益處和安全性。 該研究成果發表在《自然·通訊》上 今年早些時候
InTandem Indication and Intended Use
InTandem is indicated to improve walking and ambulation in chronic stroke, and is intended to be used in the home for the physical rehabilitation of ambulatory adults. For full prescriber information, including important safety information and Instructions for Use (IFU) visit: .
InTandem適應症和預期用途
InTandem適用於改善慢性中風患者的行走和步態,在家中用於成年人的物理康復。有關完整的處方信息,包括重要的安全信息和使用說明,請訪問: .
About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of products across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. In 2021, the company partnered with Universal Music Group and raised a Series B financing round led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine.
For more information, visit .
關於MedRhythms
MedRhythms正在開發下一代神經治療產品,旨在通過專有的、獲得專利的技術平台改善行走、機動性和相關的功能結果。該公司的平台結合了傳感器、軟件和音樂,利用先進的神經科學技術來作用於神經迴路。該公司正在開發針對一系列神經疾病的產品,包括中風、多發性硬化和帕金森病。2021年,該公司與環球音樂集團合作,並由晨興資本和優勢資本領投完成了一輪 b 輪融資。MedRhythms總部位於緬因州波特蘭。
要獲取更多信息,請訪問.
MedRhythms and InTandem are trademarks of MedRhythms, Inc.
MedRhythms和InTandem是MedRhythms, Inc.的商標。
Forward-Looking Statements
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.
前瞻性聲明
本管理評論包含一些基於我們所掌握信息的與本公司有關的前瞻性聲明和信息。不是歷史事實的聲明,包括有關公司信念、設計、預期、目標、期望和潛在結果的聲明,都屬於前瞻性聲明。此外,「將會」,「可能」,「相信」,「預期」,「打算」,「估計」,「期望」,「預測」,「計劃」,「應該」,「可能」,以及類似的表達方式,及其變體和否定形式,將會被用於識別公司或公司未來業績的前瞻性聲明。這類前瞻性聲明涉及已知和未知的風險、不確定性、假設以及其他可能導致公司實際結果、表現或業績與任何未來結果、表現或業績有實質不同的重要因素。本管理評論僅代表發表日期,公司不承諾將來更新此評論。
CONTACT
[email protected]
聯繫方式
[email protected]
SOURCE MedRhythms
MedRhythms來源於MedRhythms